Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal.
Many prospective studies and a recent randomized controlled trial have shown that the B-cell-depleting monoclonal antibody, rituximab, safely promotes the remission of nephrotic syndrome in approximately 65% of patients with membranous nephropathy (MN). Mechanistic studies have indicated that rituximab-induced proteinuria reduction is associated with clearance of anti-podocyte antigens phospholipase 2 receptor autoantibodies and subepithelial immune complexes, the hallmarks of the disease. A recently published study reported results which, at first sight, looked less favorable and implied that, due to a publication bias against negative results, the efficacy of rituximab in MN might be overestimated. Since patients received only one or 2 rituximab administrations, the authors suggest that when rituximab is used, higher doses and longer treatments should be considered. In this study, we highlight limitations of the study and warn against an oversimplified interpretation of the data. Though information on the optimal dose of rituximab to use in MN is still limited, available data from studies with predefined rituximab administration protocols collectively support the concept of titrating rituximab to the number of circulating B-cells that are invariably depleted after the first or second administration. Additional doses may increase the risk of adverse effects and related costs without augmenting efficacy. Importantly, underpowered studies with inconclusive results should not be confused with negative studies formally proving a neutral effect of a treatment. Until data from ad hoc designed clinical trials are available, the B-cell-driven protocol should be the preferred regimen, since it is similarly effective, but safer and more cost effective than other protocols employing multiple rituximab administrations.
Renal Division, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA.
Paolo
P
Cravedi
D001402:B-Lymphocytes / Q000276:immunology; D002985:Clinical Protocols; D015433:Glomerulonephritis, Membranous / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008212:Lymphocyte Depletion; D000069283:Rituximab / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D000069283:Rituximab
Kidney Int. 2012 Oct;82(8):840-56
22895519
Nephrol Dial Transplant. 2016 Jul 6;:null
27387472
N Engl J Med. 2008 Jan 17;358(3):252-60
18199864
Clin J Am Soc Nephrol. 2007 Sep;2(5):932-7
17702725
N Engl J Med. 2014 Dec 11;371(24):2277-87
25394321
J Clin Epidemiol. 2012 May;65(5):488-92
22342262
Lancet. 2015 May 16;385(9981):1983-92
26090644
N Engl J Med. 2009 Jul 2;361(1):11-21
19571279
J Psychiatry Neurosci. 2012 May;37(3):149-52
22515987
Lancet. 2002 Sep 21;360(9337):923-4
12354476
J Am Soc Nephrol. 2012 Aug;23(8):1416-25
22822077
J Am Soc Nephrol. 2017 Jan;28(1):348-358
27352623
J Am Soc Nephrol. 2015 Oct;26(10 ):2545-58
25804280
Clin J Am Soc Nephrol. 2009 Apr;4(4):734-44
19279120
Nephron Clin Pract. 2014;128(3-4):261-9
25427622
Am J Nephrol. 2011;33(5):461-8
21508634
Nat Clin Pract Nephrol. 2009 Feb;5(2):76-7
19048001
N Engl J Med. 1992 Aug 27;327(9):599-603
1640953
Clin J Am Soc Nephrol. 2008 Nov;3(6):1652-9
18684896
Clin J Am Soc Nephrol. 2006 Jul;1(4):738-48
17699281
J Nephrol. 2005 May-Jun;18(3):328-33
16013025
J Am Soc Nephrol. 2011 Aug;22(8):1543-50
21784898
Clin J Am Soc Nephrol. 2010 Dec;5(12):2188-98
20705965